Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and pharmacokinetics of oral [14C] TAS-115 in healthy adult males
jRCT2071210058Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pamufetinib in Chronic fibrosing interstitial lung disease (PF-ILD), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetics of TAS-115 and metabolites, Excretion of radioactivity into urine and feces and 2 more. Started Nov 2021; status: completed.
02
Drugs
pamufetinib
03
Conditions
Chronic fibrosing interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on jRCT2071210058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210058.